Hyperbaric Chamber for Mental Health: HBOT for PTSD, Depression & Dementia

Hyperbaric oxygen therapy (HBOT) has the strongest mental health evidence for post-traumatic stress disorder in veterans, where a 2022 randomized controlled trial reported a net effect size of 1.64 after 60 sessions, confirmed by fMRI. Evidence for depression is mostly limited to post-stroke and post-injury cases, and evidence for anxiety, ADHD, and dementia remains preliminary or absent. HBOT is not FDA-approved for any psychiatric condition.

Why Is HBOT Being Studied for Mental Health?

HBOT is studied for mental health because it targets biological mechanisms now linked to psychiatric illness: chronic neuroinflammation, mitochondrial dysfunction, and reduced cerebral blood flow. It also stimulates neuroplasticity and angiogenesis. These pathways sit alongside, not in place of, the neurotransmitter models that psychiatric medications address.

The inflammation link is well documented. A 2010 meta-analysis by Dowlati et al. in Biological Psychiatry found that people with major depressive disorder have significantly elevated levels of the pro-inflammatory cytokines TNF-alpha and IL-6 compared with controls (Dowlati et al., Biological Psychiatry, 2010). HBOT has measurable anti-inflammatory effects. A 2024 review by Bin-Alamer et al. in Frontiers in Neurology described how HBOT reduces TNF-alpha and IL-6 while supporting mitochondrial biogenesis, neurogenesis through VEGF and ERK signaling, and synaptogenesis through GAP43 and synaptophysin (Bin-Alamer et al., Frontiers in Neurology, 2024).

The mitochondrial angle is a second area of active research. The brain is about 2 percent of body weight but consumes roughly 20 percent of the body’s oxygen. A 2015 review by Klinedinst and Regenold in the Journal of Bioenergetics and Biomembranes argued that impaired mitochondrial energy production may contribute to depression through inflammation, oxidative stress, and reduced neuroplasticity (Klinedinst and Regenold, Journal of Bioenergetics and Biomembranes, 2015). HBOT increases the oxygen available for mitochondrial energy production, which is the mechanistic rationale researchers cite when they test it in psychiatric populations.

These mechanisms are plausible and partly demonstrated in imaging and biomarker studies. They are not the same as proof that HBOT treats any specific psychiatric disorder. The sections below grade each condition on its own evidence. For a broader look across conditions, see the HBOT research overview.

HBOT Mental Health Trials at a Glance

Does HBOT Work for PTSD?

PTSD has the strongest HBOT evidence of any mental health application, but it is not settled. Two randomized controlled trials in treatment-resistant and combat-associated PTSD reported large benefits, while several sham-controlled military trials in post-concussion symptoms found no oxygen-specific effect. The strongest results come from small, single-center studies awaiting large multi-site confirmation.

The landmark trial is Doenyas-Barak et al. (2022) in PLOS ONE. It randomized 35 veterans with treatment-resistant PTSD (18 to HBOT, 17 to control); 29 completed the protocol of 60 daily sessions at 2 ATA. The HBOT group showed a net effect size of 1.64 on CAPS-5 scores, one of the largest effect sizes reported for any PTSD intervention, with fMRI and DTI confirming changes in the dorsolateral prefrontal cortex, hippocampus, and fronto-limbic white matter (Doenyas-Barak et al., PLOS ONE, 2022).

A longitudinal follow-up of 22 of these veterans, published in Military Medicine in 2023, found the gains held roughly two years later. CAPS-5 scores stayed improved versus baseline (26.6 vs 47.5, P<0.001), employment rose from 41 percent to 73 percent (P=0.033), and partnership rates rose from 46 percent to 77 percent (Doenyas-Barak et al., Military Medicine, 2023).

A second randomized, sham-controlled trial by the same group, published in the Journal of Clinical Psychiatry in 2024, tested HBOT in 56 veterans with combat-associated PTSD (28 HBOT, 28 sham). The treatment group had a response rate of 68 percent versus 4 percent for sham, with CAPS-5 scores falling from 42.6 to 25.8 (Doenyas-Barak et al., Journal of Clinical Psychiatry, 2024). Earlier work by Harch et al. (2017) in Medical Gas Research treated 30 military members with blast-induced mild TBI, post-concussion syndrome, and PTSD, reporting symptom and SPECT imaging improvements in an uncontrolled design (Harch et al., Medical Gas Research, 2017).

The counterweight matters. Four sham-controlled military trials of HBOT for persistent post-concussion symptoms, which overlap heavily with PTSD, found HBOT no better than sham. Wolf et al. (2012) in the Journal of Neurotrauma (n=50), Cifu et al. (2014) in Annals of Neurology, Miller et al. (2015, the HOPPS trial) in JAMA Internal Medicine, and Weaver et al. (2018, the BIMA trial) in Undersea and Hyperbaric Medicine all reported that both HBOT and sham groups improved similarly. In 2018 the Department of Defense advised against prescribing HBOT for persistent post-concussion symptoms, consistent with the VA/DoD clinical practice guideline. A 2024 systematic review and dosage analysis by Andrews and Harch in Frontiers in Neurology reconciled some of this by finding a dose-response relationship: symptomatic improvement rose with cumulative oxygen dose across the eight studies reviewed (Andrews and Harch, Frontiers in Neurology, 2024).

To settle the question, the University of South Florida is running a large randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov NCT06581003) enrolling roughly 420 veterans with TBI and PTSD outcomes, funded at about 28 million dollars. Until it reports, HBOT for PTSD should be viewed as promising but unproven at scale. For the condition-specific detail, see our HBOT for PTSD page and the veterans and HBOT guide.

Does HBOT Help Depression?

The depression evidence is real but narrow. It is strongest for depression that follows a stroke or brain injury, where randomized trials and a large meta-analysis show benefit. Evidence for primary standalone major depression is thin, drawn mostly from pooled analyses with high variability rather than dedicated trials in otherwise healthy patients.

The clearest signal is in post-stroke depression. Tang et al. (2026), a randomized sham-controlled trial in Neuropsychiatric Disease and Treatment, enrolled 61 patients (29 HBOT, 32 sham). HAMD depression scores fell more in the HBOT group at week 2 (P=0.017) and week 4 (P<0.01), with parallel rises in serum BDNF and beta-NGF. Reductions in depression correlated with BDNF increases (r=0.66), giving both a clinical and a biological readout (Tang et al., Neuropsychiatric Disease and Treatment, 2026). A 2020 meta-analysis by Liang et al. in Clinical Neurology and Neurosurgery pooled 27 randomized trials and 2,250 patients with post-stroke depression, finding a response rate of 69.4 percent with HBOT versus 51.2 percent for controls, with fewer adverse events (Liang et al., Clinical Neurology and Neurosurgery, 2020).

For depression more broadly, a 2026 systematic review and meta-analysis by Al-Shamali et al. in Psychiatry and Clinical Neurosciences pooled 17 studies (920 participants, 9 randomized trials) across psychiatric disorders and found a large effect on depressive symptoms, Cohen’s d of -0.82. The authors flagged high statistical heterogeneity (I2 = 82 percent), meaning results varied widely between studies (Al-Shamali et al., Psychiatry and Clinical Neurosciences, 2026). That caveat is the honest headline: the average effect is large, but the underlying trials are inconsistent, small, and often in comorbid populations rather than primary major depressive disorder. HBOT is not an established depression treatment. For the deeper review, see our HBOT for depression guide.

Can HBOT Treat Anxiety?

No. There is no controlled evidence that HBOT treats anxiety disorders as a primary condition. The available data comes from studies of PTSD, TBI, and post-COVID recovery where anxiety improved as a secondary outcome. No randomized trial has tested HBOT for generalized anxiety, panic, or social anxiety disorder.

In several PTSD and TBI studies, participants reported lower anxiety alongside improvement in their primary condition, which is consistent with shared mechanisms like neuroinflammation and reduced cerebral blood flow. That is a reasonable hypothesis, not proof. Anyone considering HBOT for anxiety should understand it is being used off-label with no direct trial support, and that first-line treatments (psychotherapy and medication) have a far stronger evidence base.

What About HBOT for ADHD?

HBOT is not an evidence-based treatment for ADHD. No randomized or controlled trial supports its use for attention-deficit/hyperactivity disorder. The rationale sometimes cited, that ADHD involves reduced prefrontal blood flow, is a mechanism, not a demonstrated treatment effect.

What exists in the literature is limited to case reports and ADHD-adjacent symptom changes buried inside pediatric concussion and autism studies. None of it meets the bar for a treatment recommendation. Families exploring options should treat HBOT for ADHD as unproven and prioritize interventions with established evidence. Our HBOT for ADHD page reviews the thin literature in full.

Can HBOT Help Dementia and Memory Loss?

The human evidence for HBOT in dementia is limited and mixed, and no regulator endorses it. Most support comes from animal models and small pilots. A 2024 meta-analysis reported cognitive gains, but every included trial was unblinded and conducted in a single country, so the positive numbers must be read with heavy caution.

The strongest mechanistic work is preclinical. Shapira et al. (2018) in Neurobiology of Aging found that HBOT reduced amyloid, phosphorylated tau, and neuroinflammation and improved behavior in the 3xTg-AD mouse model (Shapira et al., Neurobiology of Aging, 2018). A follow-up by Shapira et al. (2021) in Aging combined an Alzheimer’s mouse model with a pilot of six older adults with memory decline, reporting improved cerebral blood flow and memory after 60 sessions (Shapira et al., Aging, 2021). Six patients is a pilot signal, not evidence of efficacy.

The largest pooled analysis, Lin et al. (2024) in Frontiers in Aging Neuroscience, reviewed 11 randomized trials and 847 participants and concluded HBOT improved MMSE and ADAS-Cog scores. The authors themselves cautioned that all 11 trials were conducted in China, none blinded participants or assessors, and most had small samples, which they said could produce subjective bias (Lin et al., Frontiers in Aging Neuroscience, 2024). The FDA specifically lists Alzheimer’s disease among conditions HBOT is marketed for but not proven to treat. Read these results as a reason for rigorous trials, not as a treatment endorsement. See our HBOT for dementia, Alzheimer’s and HBOT, and memory loss pages for the full picture.

How Is HBOT Used for TBI-Related Mental Health?

The clearest use case sits at the overlap of brain injury and psychiatric symptoms. Traumatic brain injury is a strong risk factor for PTSD, depression, and anxiety, and several HBOT studies in mild TBI reported improvements in mood and PTSD symptoms alongside cognitive gains. This is where mechanism and outcome line up best.

The anchor study is Boussi-Gross et al. (2013) in PLOS ONE, a randomized crossover trial of 56 patients with prolonged post-concussion syndrome one to five years after mild TBI. HBOT produced cognitive and quality-of-life improvements, with SPECT imaging showing increased brain activity in injured regions (Boussi-Gross et al., PLOS ONE, 2013). Because TBI, PTSD, and depression share inflammatory and perfusion-related mechanisms, treatments aimed at the injury may move the psychiatric symptoms with it. The caveat is the same as in the military post-concussion trials: sham groups sometimes improve too. For the injury-focused evidence, see our HBOT and brain injury page and the broader neurological conditions pillar.

What Protocols Are Used for Mental Health?

There is no single accepted protocol. Across the published psychiatric and neurological trials, most used 1.5 to 2.0 ATA for 20 to 60 sessions, with PTSD studies clustering at 40 to 60 sessions. Parameters vary by condition, severity, and clinician judgment, and no protocol is FDA-approved for a mental health indication.

Pressure: most mental health studies used 1.5 to 2.0 ATA, with some researchers favoring 1.5 ATA for psychiatric applications.

Session length: typically 60 to 90 minutes of oxygen breathing at pressure.

Course: generally 20 to 60 sessions, with PTSD protocols commonly running 40 to 60 daily sessions, five days per week.

For what a course actually involves, see our HBOT sessions guide. Because HBOT is off-label for every psychiatric use, insurance coverage for these indications is unlikely.

Who Should Not Try HBOT?

HBOT is generally safe when delivered by trained staff, but it is not appropriate for everyone. Some conditions are absolute contraindications, others require caution. Anyone considering HBOT for a mental health reason should review their full history with both a mental health provider and a hyperbaric physician first.

Absolute contraindications

• Untreated pneumothorax (collapsed lung). Pressure changes can worsen it and become life-threatening.
• Certain chemotherapy drugs. Bleomycin, cisplatin, doxorubicin, and disulfiram can interact dangerously with high-oxygen environments.

Relative contraindications

• Upper respiratory infection or sinus congestion. Difficulty equalizing pressure can cause ear or sinus barotrauma.
• Seizure disorder. High-pressure oxygen can lower the seizure threshold in susceptible people.
• COPD. Altered breathing drive may require modified protocols.
• High fever. Increases the risk of oxygen toxicity.
• History of ear surgery or chronic ear problems. Pressure equalization may be difficult.
• Claustrophobia. May require a strategy for managing enclosed spaces, relevant for patients with anxiety.
• Pregnancy. Safety data for routine use is insufficient.

Always consult your physician first, especially if you use insulin (blood sugar can drop during treatment), have an implanted device, or take other medications. For the full risk picture, see our guide to HBOT side effects.

What Is the Honest State of the Evidence?

HBOT for mental health is a research field, not a proven therapy. The best-supported use is treatment-resistant and combat-associated PTSD in veterans, where two randomized trials showed large benefits, tempered by several military post-concussion trials that found no effect over sham. Everything else is weaker.

What the evidence supports: a genuine and biologically plausible signal in PTSD, particularly with co-occurring TBI, and in depression that follows stroke or brain injury. These are backed by randomized trials and imaging.

What the evidence does not support: HBOT as a primary or standalone treatment for any psychiatric condition. Studies are generally small and single-center, some sham-controlled trials are null, and dementia and ADHD evidence is preclinical, unblinded, or absent.

The responsible position: HBOT should be considered, if at all, as a complement to established care such as psychotherapy and medication, not a replacement. Discuss it with both a mental health provider and an experienced hyperbaric physician, and keep expectations calibrated to what the trials actually show. For ongoing updates, see our HBOT research page.